TheraRadar
← Back
Data updated: Jun 28, 2026

NEXAIR

Pharma
Pharmaceuticals

NEXAIR is a pharmaceutical company with 3 FDA-approved products.

2013
Since
3
Drugs
-
Trials
8
New Drugs (2yr)
Modality:
3 Small Molecules

NEXAIR's Key Drugs

NEXAIR's core commercial portfolio centers on MEDICAL AIR, USP, CARBON DIOXIDE, USP, HELIUM, USP — its most strategically important drugs approved in the last 15 years.

MEDICAL AIR, USP
Respiratory
Approved 2013
CARBON DIOXIDE, USP
Respiratory
Approved 2013
HELIUM, USP
Respiratory
Approved 2013

NEXAIR's Recent FDA Approvals

NEXAIR secured 8 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

MEDICAL AIR, USP NDA
2026-02-17
CARBON DIOXIDE, USP NDA
2025-10-25
carbon dioxide
CARBON DIOXIDE, USP NDA
2025-06-16
carbon dioxide
CARBON DIOXIDE, USP NDA
2025-04-21
carbon dioxide
Carbon Dioxide, USP NDA
2025-02-02
carbon dioxide
Carbon Dioxide, USP NDA
2024-11-09
carbon dioxide, usp
CARBON DIOXIDE, USP NDA
2024-08-10
carbon dioxide
MEDICAL AIR, USP NDA
2024-07-13
medical air

NEXAIR's Therapeutic Areas

Disease areas where NEXAIR has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

NEXAIR Pipeline Snapshot

Active clinical trials for NEXAIR across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • MEDICAL AIR, USP leads revenue
  • • 3 key drugs tracked

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling